![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: NEURL3 |
Gene summary for NEURL3 |
![]() |
Gene information | Species | Human | Gene symbol | NEURL3 | Gene ID | 93082 |
Gene name | neuralized E3 ubiquitin protein ligase 3 | |
Gene Alias | LINCR | |
Cytomap | 2q11.2 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q96EH8 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
93082 | NEURL3 | HCC1_Meng | Human | Liver | HCC | 2.48e-21 | -1.01e-02 | 0.0246 |
93082 | NEURL3 | cirrhotic1 | Human | Liver | Cirrhotic | 2.68e-02 | 1.12e-01 | 0.0202 |
93082 | NEURL3 | cirrhotic2 | Human | Liver | Cirrhotic | 1.82e-15 | 1.76e-01 | 0.0201 |
93082 | NEURL3 | HCC2 | Human | Liver | HCC | 5.88e-06 | 2.95e+00 | 0.5341 |
93082 | NEURL3 | S027 | Human | Liver | HCC | 8.54e-05 | 7.23e-01 | 0.2446 |
93082 | NEURL3 | S028 | Human | Liver | HCC | 4.52e-14 | 6.16e-01 | 0.2503 |
93082 | NEURL3 | S029 | Human | Liver | HCC | 4.14e-09 | 1.06e+00 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NEURL3 | SNV | Missense_Mutation | c.157N>T | p.Arg53Trp | p.R53W | Q96EH8 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
NEURL3 | SNV | Missense_Mutation | novel | c.340N>A | p.Glu114Lys | p.E114K | Q96EH8 | protein_coding | deleterious(0.03) | benign(0.107) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
NEURL3 | SNV | Missense_Mutation | novel | c.638N>A | p.Arg213His | p.R213H | Q96EH8 | protein_coding | tolerated(0.55) | possibly_damaging(0.528) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
NEURL3 | SNV | Missense_Mutation | novel | c.650N>A | p.Cys217Tyr | p.C217Y | Q96EH8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BG-A0MQ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NEURL3 | SNV | Missense_Mutation | novel | c.488N>A | p.Gly163Glu | p.G163E | Q96EH8 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NEURL3 | SNV | Missense_Mutation | novel | c.500N>T | p.Ala167Val | p.A167V | Q96EH8 | protein_coding | deleterious(0) | possibly_damaging(0.854) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NEURL3 | SNV | Missense_Mutation | novel | c.419N>A | p.Gly140Asp | p.G140D | Q96EH8 | protein_coding | tolerated(0.38) | benign(0.184) | TCGA-EY-A1GU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NEURL3 | SNV | Missense_Mutation | novel | c.569N>A | p.Ala190Asp | p.A190D | Q96EH8 | protein_coding | tolerated(0.25) | benign(0.001) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NEURL3 | SNV | Missense_Mutation | novel | c.56G>A | p.Arg19His | p.R19H | Q96EH8 | protein_coding | tolerated(0.54) | probably_damaging(0.912) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
NEURL3 | SNV | Missense_Mutation | novel | c.631N>T | p.Asn211Tyr | p.N211Y | Q96EH8 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-77-A5G6-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |